Updated:
Clario
Clario, a part of Thermo Fisher Scientific, combines science-informed endpoint technology, global scale, and expert services to generate reliable clinical...
Overview
Clario, a part of Thermo Fisher Scientific, combines science-informed endpoint technology, global scale, and expert services to generate reliable clinical evidence for every trial phase.
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Philadelphia
Corporate office
Philadelphia, PA, United States
Additional offices
Montréal, QC, Canada
Sector focus
Frequently asked questions
Who owns Clario?
Clario is a business unit of Thermo Fisher Scientific, a publicly traded life sciences company. The firm presents itself as 'part of Thermo Fisher Scientific' on its website and corporate materials.
What endpoint technologies does Clario offer?
Clario offers a broad endpoint technology platform that includes cardiac safety (ECG, blood pressure monitoring, arrhythmia analysis), electronic clinical outcome assessments (eCOA), medical imaging (CT, MRI, endoscopy with AI redaction), precision motion (wearable sensors for mobility endpoints), and respiratory solutions (spirometry, cough and lung sound analysis).
What therapeutic areas does Clario focus on?
Clario covers cardiovascular and metabolic, dermatology, diabetes and obesity, gastroenterology, hepatology, infectious diseases, musculoskeletal, neuroscience (dementias, headache disorders, movement disorders, multiple sclerosis, pain, psychiatric), oncology, ophthalmology, and respiratory.
Does Clario use artificial intelligence in its services?
Yes, Clario deploys AI in several areas, notably its Image Redact AI tool that automatically redacts patient identifiers from medical images, videos, and PDFs. The firm also uses AI in respiratory data interpretation and across its imaging platform.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: